173 related articles for article (PubMed ID: 25201286)
1. Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
Cascella R; Strafella C; Ragazzo M; Zampatti S; Borgiani P; Gambardella S; Pirazzoli A; Novelli G; Giardina E
Pharmacogenomics J; 2015 Apr; 15(2):196-200. PubMed ID: 25201286
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M
Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625
[TBL] [Abstract][Full Text] [Related]
4. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore.
Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP
Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386
[No Abstract] [Full Text] [Related]
5. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
[TBL] [Abstract][Full Text] [Related]
6. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
7. Abacavir pharmacogenetics--from initial reports to standard of care.
Martin MA; Kroetz DL
Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
[TBL] [Abstract][Full Text] [Related]
8. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?
To SW; Chen JH; Wong KH; Chan KC; Tsang OT; Yam WC
Int J STD AIDS; 2013 Jan; 24(1):50-2. PubMed ID: 23512513
[TBL] [Abstract][Full Text] [Related]
9. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
10. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.
Parczewski M; Leszczyszyn-Pynka M; Wnuk A; Urbañska A; Fuksiñska K; Bander D; Boroñ-Kaczmarska A
HIV Med; 2010 May; 11(5):345-8. PubMed ID: 20070406
[TBL] [Abstract][Full Text] [Related]
11. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
12. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
Dello Russo C; Lisi L; Lofaro A; Di Giambenedetto S; Federico B; Madeddu G; Salerno M; Mura MS; Pirazzoli A; de Luca A; Cauda R; Navarra P
Pharmacogenomics; 2011 Apr; 12(4):567-76. PubMed ID: 21521028
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L
PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872
[TBL] [Abstract][Full Text] [Related]
14. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.
Sanchez-Giron F; Villegas-Torres B; Jaramillo-Villafuerte K; Silva-Zolezzi I; Fernandez-Lopez JC; Jimenez-Sanchez G; Carnevale A
Pharmacogenomics; 2011 Jun; 12(6):809-14. PubMed ID: 21510768
[TBL] [Abstract][Full Text] [Related]
15. Successful translation of pharmacogenetics into the clinic: the abacavir example.
Phillips E; Mallal S
Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
[TBL] [Abstract][Full Text] [Related]
16. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
[No Abstract] [Full Text] [Related]
17. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
[TBL] [Abstract][Full Text] [Related]
18. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
[TBL] [Abstract][Full Text] [Related]
20. A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.
Giardina E; Stocchi L; Foti Cuzzola V; Zampatti S; Gambardella S; Patrizi MP; Bramanti P; Pirazzoli A; Novelli G
Electrophoresis; 2010 Oct; 31(21):3525-30. PubMed ID: 20925049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
